Result:Weak
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 0.00 | ||
| Total Income | 0.00 | 100.0% | |
| Expenditure | 0.24 | 41.3% | 4.1% |
| PBT | -0.24 | 35.6% | 4.1% |
| Net Profit | -0.24 | 33.8% | 8.1% |
| OPM | — | ||
| NPM | — | ||
| EPS | 0.12 | 36.8% | 0.0% |
No revenue and a continuing net loss with PAT declining further YoY (-8.1%) show no improvement in the core pharma business, though the loss narrowed marginally in absolute magnitude so it's not deteriorating sharply.
Informational and educational content only. Not investment advice.